#United States #Ann Arbor #Fabry disease #Genomenon #Amicus Therapeutics

Advancing Fabry Disease Awareness Through Collaboration

In a significant move towards improving the awareness and diagnosis of Fabry disease, Genomenon has announced a strategic partnership with Amicus Therapeutics. This collaboration is aimed at enhancing research efforts and providing critical insights into genetic variants that play a key role in this rare condition.

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A (α-Gal A), which is encoded by the GLA gene. The absence of this enzyme results in the accumulation of globotriaosylceramide (GL-3) within the body's cells, leading to serious complications affecting the heart, brain, kidneys, and skin. Due to its rarity and symptoms overlapping with other conditions, diagnosing Fabry disease can be challenging, making timely and accurate identification crucial for patient outcomes.

The Collaboration Initiative

Through their collaboration, Genomenon and Amicus Therapeutics have launched a concerted effort to produce real-world evidence derived from literature, utilizing artificial intelligence and expert review to curate and classify variants in the GLA gene. The data obtained from this initiative has been made freely accessible to the global clinical and research communities via the Mastermind Genomic Intelligence Platform, and it has also been submitted to ClinVar. ClinVar is a widely respected public archive hosted by the National Center for Biotechnology Information (NCBI), which catalogs variations in human genes.

As part of this initiative, Genomenon has provided information on over 1,300 GLA variants to ClinVar, with more than 1,000 of these designated as either pathogenic or likely pathogenic. Notably, over 50% of these pathogenic variants had not been previously reported in ClinVar, significantly augmenting the body's knowledge regarding Fabry disease and its genetic underpinnings.

Supporting Clinicians and Patients

The partnership not only aims to broaden access to crucial genetic variant data but also strives to facilitate faster and more confident interpretation of genetic tests. By reducing delays in diagnosing patients, Genomenon and Amicus Therapeutics are working towards a future where families affected by Fabry disease can gain clarity and timely support.

Dr. Jeff Castelli, Chief Development Officer of Amicus Therapeutics, emphasized the significance of this partnership: "This sponsorship with Genomenon expands access to high-quality genetic insights that can accelerate diagnosis and support more informed clinical decisions. By combining our Fabry expertise with Genomenon's genomic intelligence, we hope to help more patients receive clarity earlier in their diagnostic journey, ultimately improving outcomes for individuals and families around the world."

Additionally, Mike Klein, the CEO of Genomenon, stated, "This sponsorship is about removing barriers to genetic diagnosis so fewer patients are left waiting for clarity. With rare diseases like Fabry, patients may remain undiagnosed for years. By making expertly curated GLA variant evidence publicly available, we're expanding access to critical data and helping clinicians identify patients who may otherwise never receive a diagnosis."

About Genomenon

Genomenon is a pioneering company in the realm of genomic intelligence, focusing on transforming biomedical literature into structured, real-world evidence. Their partnerships with pharmaceutical organizations facilitate accelerated drug development, particularly in rare diseases and precision oncology. By enhancing disease understanding and aiding clinical trial design, Genomenon contributes significantly to improving patient care.

For more information, visit Genomenon or follow them on LinkedIn for updates on their latest initiatives and partnerships.